LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients

By Natalie GoodridgeApril 26, 2017October 29th, 2024Healthcare

No Comments

LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients

https://www.businesswire.com/news/home/20170426005165/en/LimFlow-Receives-FDA-Approval-U.S.-Feasibility-Study

Tags:

Healthcare LimFlow

PreviousMidterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia
NextCagent Vascular announces FDA 510(k) clearance of Serranator Alto serration balloon catheter

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality

Healthcare

Shipping

Alternatives

Media room

About

Contact

Copyright © 2025 M&L Group. All Rights Reserved. | Legal.

Branding and website design by Stepworks